According to a U.S. Justice Department press release, Intermune, a California-based biopharmaceutical manufacturer, agreed to pay the U.S. Government $39.2 million in settlement of Government charges that Intermune caused false claims to be submitted to Medicare, Medicaid, TRICARE, and the FEHB Program based on its illegal promotion of its Actimmune drug for a use — the treatment of lung scarring — that the Food and Drug Administration had not approved.